FP07.13 Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer

Abstract

suggests that NGS platforms, academic or commercially available, would also improve their detection rate by capturing the full breadth of variants that have been identified.

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

“…This article aims to describe the clinicopathologic characteristics of KRAS G12D lung cancer and outcomes within this population by co-mutation status. Though recent work has compared outcomes for patients across KRAS mutation subtypes, 7 , 8 , 9 , 10 , 11 or in comparison with KRAS wild-type NSCLC, 12 relatively little is known about the specific characteristics and outcomes for patients with KRAS G12D-mutant NSCLC. This is a considerable gap in the literature, and an understanding of how patients with G12D lung cancer fared before the advent of G12D-specific inhibitors will be needed.…”